Liu, Chang, Das, Raksha, Dijokaite-Guraliuc, Aiste, Zhou, Daming, Mentzer, Alexander J., Supasa, Piyada, Selvaraj, Muneeswaran, Duyvesteyn, Helen M. E., Ritter, Thomas G., Temperton, Nigel J., and others. (2024) Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection. Nature Communications, 15 (1). Article Number 3284. E-ISSN 2041-1723. (doi:10.1038/s41467-024-47393-3) (KAR id:105647)
|
PDF
Publisher pdf
Language: English 
This work is licensed under a Creative Commons Attribution 4.0 International License.
|
|
|
Download this file (PDF/3MB) |
Preview |
| Request a format suitable for use with assistive technology e.g. a screenreader | |
| Official URL: https://doi.org/10.1038/s41467-024-47393-3 |
|
Abstract
The rapid evolution of SARS-CoV-2 is driven in part by a need to evade the antibody response in the face of high levels of immunity. Here, we isolate spike (S) binding monoclonal antibodies (mAbs) from vaccinees who suffered vaccine break-through infections with Omicron sub lineages BA.4 or BA.5. Twenty eight potent antibodies are isolated and characterised functionally, and in some cases structurally. Since the emergence of BA.4/5, SARS-CoV-2 has continued to accrue mutations in the S protein, to understand this we characterize neutralization of a large panel of variants and demonstrate a steady attrition of neutralization by the panel of BA.4/5 mAbs culminating in total loss of function with recent XBB.1.5.70 variants containing the so-called ‘FLip’ mutations at positions 455 and 456. Interestingly, activity of some mAbs is regained on the recently reported variant BA.2.86.
| Item Type: | Article |
|---|---|
| DOI/Identification number: | 10.1038/s41467-024-47393-3 |
| Additional information: | For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. |
| Uncontrolled keywords: | Humans, Postoperative Complications, Antibodies, Monoclonal, Antibodies, Viral, Mutation, Antibodies, Neutralizing, SARS-CoV-2 |
| Subjects: | Q Science > QR Microbiology > QR355 Virology |
| Divisions: | Divisions > Division of Natural Sciences > Medway School of Pharmacy |
| Funders: |
Wellcome Trust (https://ror.org/029chgv08)
Medical Research Council (https://ror.org/03x94j517) |
| Depositing User: | Nigel Temperton |
| Date Deposited: | 16 Apr 2024 17:10 UTC |
| Last Modified: | 05 Nov 2024 13:11 UTC |
| Resource URI: | https://kar.kent.ac.uk/id/eprint/105647 (The current URI for this page, for reference purposes) |
University of Kent Author Information
Temperton, Nigel J..
| Creator's ORCID: |
 https://orcid.org/0000-0002-7978-3815
|
|---|---|
| CReDIT Contributor Roles: |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):
Altmetric
Altmetric
